By Inti Landauro
PARIS--French pharmaceutical company Sanofi SA (SAN.FR) Thursday
said a study showed positive results from the second year of an
extension of trials made on multiple sclerosis patients treated
with its new drug Lemtrada, developed by its unit Genzyme.
Sanofi said relapse rates and sustained accumulation of
disability remained low among patients who had previously received
Lemtrada--also known as Alemtuzumab--in either of the Phase III
CARE-MS I and CARE-MS II studies.
"These extension study results provide further evidence of the
prolonged efficacy of Lemtrada on both relapses and disability,"
said Dr. Alasdair Coles, senior lecturer at the Department of
Clinical Neurosciences at the University of Cambridge, according to
a Sanofi statement.
Sanofi has decided to resubmit the application to the the U.S.
Food and Drug Administration to authorize the new
multiple-sclerosis drug, following a first rejection in late
2013.
Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires